New COVID vaccine shows promise in both needle and nasal spray forms
NCT ID NCT05205746
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single dose of a new COVID-19 vaccine (AVX/COVID-12) in 158 healthy adults who already had some immunity to the virus. The vaccine was given either as an injection or a nasal spray to see which route worked better and was safe. Researchers measured antibody and T-cell responses to understand how well the vaccine boosted protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CAIMED Investigación en Salud S.A. de C.V.
Mexico City, Mexico City, 06760, Mexico
-
Centro Mexicano de Estudios Clínicos CEMDEC SA de CV
Mexico City, Mexico City, 06100, Mexico
-
Oaxaca Site Management Organization S.C.
Oaxaca City, Oaxaca, 68000, Mexico
-
Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro Social
Mexico City, Mexico City, 07760, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a digital swab test tell COVID and flu apart at home?
- Sniffing your way back: does scent therapy rebuild COVID-Shattered smell?
- Long-Term heart risks after rare COVID complication in kids under scrutiny
- Which COVID-19 shot causes fewer side effects? new study compares novavax and pfizer
- New study tracks immune clues in seniors with flu, RSV, and COVID-19
- MRI study seeks clues to COVID brain fog